New Generation Expands In AstraZeneca's Vacated Campus
This article was originally published in Scrip
When AstraZeneca plc decided three years ago to relocate its R&D headquarters from its Alderley Park campus in the Northwest of England to be nearer the biotech action around Cambridge, a research park built to accommodate thousands of scientists suddenly faced the prospect of becoming a ghost town. However, for Dr Neil Murray, CEO of local firm Redx Pharma, the site represents a great opportunity.
You may also be interested in...
After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.